EP1443904A2 - Orally administered pharmaceutical preparation comprising liposomically encapsulated paclitaxel - Google Patents
Orally administered pharmaceutical preparation comprising liposomically encapsulated paclitaxelInfo
- Publication number
- EP1443904A2 EP1443904A2 EP02785050A EP02785050A EP1443904A2 EP 1443904 A2 EP1443904 A2 EP 1443904A2 EP 02785050 A EP02785050 A EP 02785050A EP 02785050 A EP02785050 A EP 02785050A EP 1443904 A2 EP1443904 A2 EP 1443904A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- pharmaceutical preparation
- preparation according
- taxol
- peg
- lipid component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- Orally administrable pharmaceutical preparation comprising liposomally encapsulated taxol
- the invention relates to pharmaceutical preparations which are suitable for the oral use of liposomally encapsulated taxol, its derivatives and taxanes. Areas of application of the invention are medicine and the pharmaceutical industry.
- Taxol (chemical: Paclitaxel) is a natural substance found in the bark of various yew species (Taxazeen), which is derived from these barks and also by chemical synthesis [J. Amer. Chem. Soc, 1110: 5917-5919 (1988)]. Taxol requires the aggregation of the microtubules from tubulin dimers and stabilizes the microtubules by inhibiting their depolymerization. Furthermore, there is an abnormal arrangement and bundling of microtubules during the entire cell cycle, which leads to the formation of multiple microtubular dividing stars during mitosis and thus to the inhibition of the normal dynamic reorganization of the microtubular network.
- Taxol Since the vital cell function in the interphase and during mitosis is thereby decisively influenced, Taxol shows a clear antineoplastic activity against various tumors, u. a. against implanted B16 melanoma, P388 leukemia and against human breast tumors.
- the applicability of Taxol is severely limited due to its low water solubility.
- Solubilizers such as cremophor (polyethoxylated castor oil) and alcohol improve the solubility, but lead to considerable side effects when used, e.g. to anaphylactoid reactions. Nerd thinning with physiological saline for application has the disadvantage that taxol in physiological saline does not have sufficient stability (maximum 24 hours).
- a dose-limiting side effect is myelosuppression, primarily neutropenia [Semin. Oncol. 19: 646-662 (1992)]. Due to their amphiphilic character, liposomes offer the possibility to include or incorporate both water- and lipid-soluble substances.
- Taxol as an almost water-insoluble substance can be dissolved with high efficiency in the lipid phase of liposomes of suitable composition, which can be used to treat different types of tumors and localizations.
- taxol in free and liposomal form was tested for anti-tumor activity on two human glioblastomas in the nude model (12.5 mg kg / 4 days). Both forms led to a significant reduction in tumor growth [In-Nivo 6 (l): 23-7 (1992)].
- WO 93/18751 describes the encapsulation of taxol in liposomes and the use of the products obtained for the treatment of cancer. A combination of this treatment with hyperthermia is preferred.
- the Taxol liposomes produced show improved stability. From DE 44 30 593 C2, a high-pressure homogenization process for the production of liposomally encapsulated taxol is known, the liposomes having a high taxol content and high stability.
- Taxol is excellent as a cytostatic, but its use is limited to parenteral preparations. An effectiveness of Taxol when administered orally has not been established internationally. Oral application forms for liposomally encapsulated taxol are also not yet known.
- Taxol was administered in an oral dosage form as a bolus of 50 mg and the effectiveness of the agent was determined on the basis of the tumor mass (ovarian carcinoma (human) on the ⁇ ude mouse).
- B and C show the effectiveness after oral application of unencapsulated taxol (B) and unencapsulated taxol in combination with cyclosporin A, with the tumor mass hardly reducing.
- the efficacy can be deduced after oral administration of liposomally encapsulated taxol, the tumor mass being significantly reduced.
- the preferred dosage for liposomally encapsulated taxol is 1 x 50 mg / kg body weight daily.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Epoxy Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to pharmaceutical preparations, which are suitable for the oral application of liposomically encapsulated paclitaxel, its derivatives and taxane. Said preparations preferably contain at least one immunomodulator, preferably cyclosporine, and/or at least one cytokine, preferably PEG-cytokine.
Description
Oral verabreichbare pharmazeutische Zubereitung umfassend liposomal verkapseltes TaxolOrally administrable pharmaceutical preparation comprising liposomally encapsulated taxol
Beschreibungdescription
Die Erfindung betrifft pharmazeutische Zubereitungen, die zur oralen Anwendung von liposomal verkapseltem Taxol, seinen Derivaten und Taxan geeignet sind. Anwendungsgebiete der Erfindung sind die Medizin und die pharmazeutische Industrie.The invention relates to pharmaceutical preparations which are suitable for the oral use of liposomally encapsulated taxol, its derivatives and taxanes. Areas of application of the invention are medicine and the pharmaceutical industry.
Taxol (chemisch: Paclitaxel) ist ein in der Rinde verschiedener Eibenarten (Taxazeen) vorkommender Naturstoff, der aus diesen Rinden und auch durch chemische Synthese [J. Amer. Chem. Soc, 1110:5917-5919 (1988)] gewonnen werden kann. Taxol fordert die Aggregation der Mikrotubuli aus Tubulindimeren und stabilisiert die Mikrotubuli durch Hemmnung ihrer Depolymerisation. Weiterhin kommt es zur einer abnormen Anordnung und Bündelung von Mikrotubuli während des gesamten Zellzyklusses, was zur Bildung multipler mikrotubulärer Teilungssterne während der Mitose und damit zur Hemmung der normalen dynamischen Reorganisation des mikrotubulären Netzwerkes fuhrt. Da dadurch die vitale Zellfunktion in der Interphase und während der Mitose entscheidend beeinflußt wird, zeigt Taxol eine deutliche antineoplastische Aktivität gegen verschiedene Tumoren, u. a. gegen implantierte B16-Melanome, P388-Leukämie und gegen humane Mammatumoren. Die Anwendbarkeit von Taxol ist durch seine geringe Wasserlöslichkeit jedoch stark eingeschränkt. Lösungsvermittler wie Cremophor (polyethoxyliertes Castoröl) und Alkohol verbessern zwar die Löslichkeit, fuhren jedoch bei der Anwendung zu erheblichen Nebenwirkungen, z.B. zu anaphylaktoiden Reaktionen. Die Nerdünnung mit physiologischer Kochsalzlösung zur Applikation hat den Nachteil, daß Taxol in physiologischer Kochsalzlösung keine ausreichende Stabilität (maximal 24 Stunden) besitzt. Eine dosislimitierende Nebenwirkung ist die Myelosuppression in erste Linie die Neutropenie [Semin. Oncol. 19:646-662 (1992)]. Liposomen bieten aufgrund ihres amphiphilen Charakters die Möglichkeit, sowohl wasser- als auch lipidlösliche Substanzen einzuschließen bzw. zu inkorpieren.Taxol (chemical: Paclitaxel) is a natural substance found in the bark of various yew species (Taxazeen), which is derived from these barks and also by chemical synthesis [J. Amer. Chem. Soc, 1110: 5917-5919 (1988)]. Taxol requires the aggregation of the microtubules from tubulin dimers and stabilizes the microtubules by inhibiting their depolymerization. Furthermore, there is an abnormal arrangement and bundling of microtubules during the entire cell cycle, which leads to the formation of multiple microtubular dividing stars during mitosis and thus to the inhibition of the normal dynamic reorganization of the microtubular network. Since the vital cell function in the interphase and during mitosis is thereby decisively influenced, Taxol shows a clear antineoplastic activity against various tumors, u. a. against implanted B16 melanoma, P388 leukemia and against human breast tumors. The applicability of Taxol is severely limited due to its low water solubility. Solubilizers such as cremophor (polyethoxylated castor oil) and alcohol improve the solubility, but lead to considerable side effects when used, e.g. to anaphylactoid reactions. Nerd thinning with physiological saline for application has the disadvantage that taxol in physiological saline does not have sufficient stability (maximum 24 hours). A dose-limiting side effect is myelosuppression, primarily neutropenia [Semin. Oncol. 19: 646-662 (1992)]. Due to their amphiphilic character, liposomes offer the possibility to include or incorporate both water- and lipid-soluble substances.
Taxol als eine fast wasserunlösliche Substanz läßt sich mit hoher Effizienz in der Lipidphase von Liposomen geeigneter Zusammensetzung lösen, welche zur Behandlung unterschiedlicher Tumorarten und Lokalisationen eingesetzt werden können. In einer Studie wurde Taxol in freier und liposomaler Form hinsichtlich der Antirumoraktivität an zwei humanen Glioblastomen im Nude-Modell getestet (12,5 mg kg/4 Tage). Beide Formen führten zu einer signifikanten Verringerung des Tumorwachstums [In-Nivo 6 (l):23-7 (1992)].
In WO 93/18751 wird die Nerkapselung von Taxol in Liposomen und die Verwendung der erhaltenen Produkte zur Behandlung von Krebserkrankungen beschrieben. Bevorzugt wird eine Kombination dieser Behandlung mit Hyperthermie. Die hergestellten Taxol-Liposomen zeigen eine verbesserte Stabilität. Aus DE 44 30 593 C2 ist ein Hochdruckhomogenisationsverfahren zur Herstellung von liposomal verkapseltem Taxol bekannt, wobei die Liposomen einen hohen Taxolanteil und eine hohe Stabilität aufweisen.Taxol as an almost water-insoluble substance can be dissolved with high efficiency in the lipid phase of liposomes of suitable composition, which can be used to treat different types of tumors and localizations. In one study, taxol in free and liposomal form was tested for anti-tumor activity on two human glioblastomas in the nude model (12.5 mg kg / 4 days). Both forms led to a significant reduction in tumor growth [In-Nivo 6 (l): 23-7 (1992)]. WO 93/18751 describes the encapsulation of taxol in liposomes and the use of the products obtained for the treatment of cancer. A combination of this treatment with hyperthermia is preferred. The Taxol liposomes produced show improved stability. From DE 44 30 593 C2, a high-pressure homogenization process for the production of liposomally encapsulated taxol is known, the liposomes having a high taxol content and high stability.
Taxol ist hervorragend als Zytostatikum verwendbar, jedoch ist seine Anwendung auf parenterale Zubereitungen beschränkt. Eine Wirksamkeit von Taxol bei oraler Anwendung konnte bisher international nicht festgestellt werden. Perorale Applikationsformen für liposomal verkapseltes Taxol sind bisher ebenfalls nicht bekannt.Taxol is excellent as a cytostatic, but its use is limited to parenteral preparations. An effectiveness of Taxol when administered orally has not been established internationally. Oral application forms for liposomally encapsulated taxol are also not yet known.
Überraschend wurde gefunden, dass pharmazeutische Zubereitungen von liposomal verkapseltem Taxol zur oralen Applikation eingesetzt werden können und in diesen Anwendungsformen eine gute und schnelle ggf. retardierende Wirksamkeit zeigen. Diese Wirksamkeit konnte noch gesteigert werden, wenn die oralen Applikationsformen neben liposomal verkapseltem Taxol weiterhin mindestens noch einen Immunmodulator und/oder mindestens ein Cytokin enthalten. Ebenfalls wirksam sind Derivate des Taxols und Taxan.Surprisingly, it was found that pharmaceutical preparations of taxol encapsulated in liposomal form can be used for oral administration and, in these forms of use, show a good and rapid, possibly retarding, activity. This effectiveness could be increased even more if the oral application forms, in addition to liposomally encapsulated taxol, still contain at least one immunomodulator and / or at least one cytokine. Derivatives of taxol and taxane are also effective.
Wie der beigefügten Abbildung entnommen werden kann, wurde Taxol in einer oralen Darreichungsform als Bolus von 50 mg appliziert und die Wirksamkeit des Mittels anhand der Tumormasse (Ovarialcarcinom (human) auf der Νude-Maus,) bestimmt.As can be seen from the attached figure, Taxol was administered in an oral dosage form as a bolus of 50 mg and the effectiveness of the agent was determined on the basis of the tumor mass (ovarian carcinoma (human) on the Νude mouse).
Anwendung A diente dabei als Kontrolle, eine Beeinflussung auf das Tumormasse konnte nicht festgestellt werden.Application A served as a control, and no influence on the tumor mass could be determined.
B und C zeigen die Wirksamkeit nach oraler Applikation von unverkapseltem Taxol (B) und von unverkapseltem Taxol in Kombination mit Cyclosporin A, wobei sich die Tumormasse kaum verringerte.B and C show the effectiveness after oral application of unencapsulated taxol (B) and unencapsulated taxol in combination with cyclosporin A, with the tumor mass hardly reducing.
D kann die Wirksamkeit nach oraler Applikation von liposomal verkapseltem Taxol entnommen werden, wobei sich die Tumormasse signifikant verringerte.D the efficacy can be deduced after oral administration of liposomally encapsulated taxol, the tumor mass being significantly reduced.
E, welches die Wirksamkeit der oralen Applikation von liposomal verkapseltem Taxol inE, which shows the effectiveness of oral application of taxol encapsulated in liposomes
Kombination mit Cyclosporin A zeigt, führte zum Verschwinden des Tumors.Combination with cyclosporin A shows led to the disappearance of the tumor.
Die bevorzugte Dosierung für liposomal verkapseltes Taxol liegt bei täglich 1 x 50 mg/kg Körpergewicht. Die Dosierung von Cyclosporin bei täglich 5 x 50 mg/kg Körpergewicht.The preferred dosage for liposomally encapsulated taxol is 1 x 50 mg / kg body weight daily. The dosage of cyclosporin at 5 x 50 mg / kg body weight daily.
Die Erfindung wird gemäß den Ansprüchen realisiert.
The invention is implemented according to the claims.
Claims
1. Oral verabreichbare pharmazeutische Zubereitung, dadurch gekennzeichnet, dass sie liposomal verkapseltes Taxol, seine Derivate oder Taxan umfasst.1. Orally administrable pharmaceutical preparation, characterized in that it comprises liposomally encapsulated taxol, its derivatives or taxanes.
2. Pharmazeutische Zubereitung nach Anspruch 1, dadurch gekennzeichnet, dass sie zusätzlich mindestens einen Immunmodulator, vorzugsweise Cyclosporine, und/oder mindestens ein Cytokin, vorzugsweise PEG-Cytokine, umfasst.2. Pharmaceutical preparation according to claim 1, characterized in that it additionally comprises at least one immunomodulator, preferably cyclosporins, and / or at least one cytokine, preferably PEG cytokines.
3. Pharmazeutische Zubereitung nach Anspruch 1 oder 2, dadurch gekennzeichnet, dass sie zusätzlich an sich übliche pharmazeutische Hilfs- und Zusatzstoffe umfasst.3. Pharmaceutical preparation according to claim 1 or 2, characterized in that it additionally comprises conventional pharmaceutical auxiliaries and additives.
4. Pharmazeutische Zubereitung nach Anspruch 1, dadurch gekennzeichnet, dass die Lipsomen, die das verkapselte Taxol mit hohem Taxolanteil aufweisen, aus a) einem natürlichen, halbsynthetischen oder vollsynthetischen Amphiphil b) einem Steroid c) einer geladenen Lipidkomponente und/oder einer gesättigten Lipidkomponente und/oder einer Etherlipidkomponente, d) einer Trägerflüssigkeit und ggf. zusätzlichen Hilfsstoffen bestehen.4. Pharmaceutical preparation according to claim 1, characterized in that the lipsomes, which have the encapsulated taxol with a high taxol content, from a) a natural, semisynthetic or fully synthetic amphiphile b) a steroid c) a charged lipid component and / or a saturated lipid component and / or an ether lipid component, d) a carrier liquid and optionally additional auxiliaries.
5. Pharmazeutische Zubereitung nach Anspruch 4, dadurch gekennzeichnet, dass das Amphiphil a) ein Lipid, Tensid, Emulgator, Polyethylenglykol (PEG) oder Lipid-PEG ist.5. Pharmaceutical preparation according to claim 4, characterized in that the amphiphile a) is a lipid, surfactant, emulsifier, polyethylene glycol (PEG) or lipid PEG.
6. Pharmazeutische Zubereitung nach Anspruch 5, dadurch gekennzeichnet, dass das Amphiphil a) die allgemeine Formel I aufweist,6. Pharmaceutical preparation according to claim 5, characterized in that the amphiphile a) has the general formula I,
CH. - O - R! CH. - O - R !
II
R2 - O - CH O CH3 R 2 - O - CH O CH 3
I ιι +/I ιι + /
CH2- O - P- O - CH2 - CH2 - N - CH3 ICH 2 - O - P- O - CH 2 - CH 2 - N - CH 3 I
I \I \
.0 CH,.0 CH,
worin R, und R2 = Cι0-C20-Alkanoyl, -Alkenoyl, -Alkyl, -Alkenyl bedeuten. where R, and R 2 = -C 0 -C 20 alkanoyl, alkenoyl, alkyl, alkenyl.
7. Pharmazeutische Zubereitung nach Anspruch 4, dadurch gekennzeichnet, dass b) das Steroid Cholesterol, Diethoxycholesterol oder Sitosterol ist.7. Pharmaceutical preparation according to claim 4, characterized in that b) the steroid is cholesterol, diethoxycholesterol or sitosterol.
8. Pharmazeutische Zubereitung nach Anspruch 4, dadurch gekennzeichnet, dass c) als geladene Lipidkomponente das Anion des Dicethylphosphats, der Palmitinsäure, der Stearinsäure, das Anion eines Phospholipids oder das Anion eines Sphingolipids, oder Polyethylenglykol (PEG) eingesetzt wird oder dass ein chemisch modifiziertes Phosphatidylethanolamin, über das Proteine angekoppelt werden können, oder Etherlipide, eingesetzt werden.8. Pharmaceutical preparation according to claim 4, characterized in that c) the charged lipid component is the anion of dicethyl phosphate, palmitic acid, stearic acid, the anion of a phospholipid or the anion of a sphingolipid, or polyethylene glycol (PEG) or that a chemically modified one Phosphatidylethanolamine, via which proteins can be coupled, or ether lipids, can be used.
9. Pharmazeutische Zubereitung nach Anspruch 8, dadurch gekennzeichnet, dass c) Phosphatidylserin, Phosphatidsäure, Phosphatidylglycerol oder Sulfatid eingesetzt wird.9. Pharmaceutical preparation according to claim 8, characterized in that c) phosphatidylserine, phosphatidic acid, phosphatidylglycerol or sulfatide is used.
10. Pharmazeutische Zubereitung nach Anspruch 4, dadurch gekennzeichnet, dass c) als neutrale Lipidkomponente Phosphatidylcholin, vorzugsweise Eiphosphatidylcholin, eingesetzt wird.10. Pharmaceutical preparation according to claim 4, characterized in that c) phosphatidylcholine, preferably egg phosphatidylcholine, is used as the neutral lipid component.
11. Pharmazeutische Zubereitung nach Anspruch 4, dadurch gekennzeichnet, dass c) als gesättigte Lipidkomponenten Dipalmitoylphosphatidylcholin oder Dimyrestoylphosphatidylcholin eingesetzt wird.11. Pharmaceutical preparation according to claim 4, characterized in that c) dipalmitoylphosphatidylcholine or dimyrestoylphosphatidylcholine is used as the saturated lipid components.
12. Pharmazeutische Zubereitung nach Anspruch 4, dadurch gekennzeichnet, dass d) Nanopartikel als zusätzliche Hilfsstoffe eingesetzt werden.12. Pharmaceutical preparation according to claim 4, characterized in that d) nanoparticles are used as additional auxiliaries.
13. Pharmazeutische Zubereitung nach Anspruch 4, dadurch gekennzeichnet, dass d) in der Membran der Vesikel als Hilfsstoff Polyethylenglykol (MG 2000 - 10000) enthalten ist.13. Pharmaceutical preparation according to claim 4, characterized in that d) is contained in the membrane of the vesicles as an auxiliary polyethylene glycol (MW 2000 - 10000).
14. Pharmazeutische Zubereitung nach Anspruch 4, dadurch gekennzeichnet, dass d) Polymerpartikel in Form einer 25%igen wässrigen Lösung Poloxamer als zusätzliche Hilfsstoffe eingesetzt werden.14. Pharmaceutical preparation according to claim 4, characterized in that d) polymer particles in the form of a 25% aqueous solution of poloxamer are used as additional auxiliaries.
15. Pharmazeutische Zubereitung nach einem der Ansprüche 4 bis 14, dadurch gekennzeichnet, dass die Mengenverhältnisse a:b:c im Molverhältnis 1:0,3:0,1 bis 1:1:0,1 oder bis 1:1:0,5 und c:d im Molverhältnis 2:1 bis 10:1 sind. 15. Pharmaceutical preparation according to one of claims 4 to 14, characterized in that the quantitative ratios a: b: c in a molar ratio of 1: 0.3: 0.1 to 1: 1: 0.1 or up to 1: 1: 0, 5 and c: d in a molar ratio of 2: 1 to 10: 1.
16. Pharmazeutische Zubereitung nach einem der Ansprüche 1 bis 14, dadurch gekennzeichnet, dass der liposomal verkapselte Wirkstoff mit hohem Wirkstoffanteil durch Verkapselung in einem Gemisch von membranbildenden Amphiphilen, in denen der Wirkstoff gelöst wurde, und einer wässrigen Phase hergestellt wurde, wobei er einer Hochdruckhomogenisation mit Drucken von 50 bis 1600 bar (5-160 Mpa) oder Ultraschall unterzogen wird.16. Pharmaceutical preparation according to one of claims 1 to 14, characterized in that the liposomally encapsulated active ingredient with a high active ingredient content was produced by encapsulation in a mixture of membrane-forming amphiphiles in which the active ingredient was dissolved and an aqueous phase, whereby it was subjected to high-pressure homogenization with pressures from 50 to 1600 bar (5-160 Mpa) or ultrasound.
17. Pharmazeutische Zubereitung nach einem der Ansprüche 1 bis 15, dadurch gekennzeichnet, dass sie vzw. in Form einer Flüssigkeit, von Tabletten, Granula, Kapseln, Pulver, Lyophilisaten vorliegt. 17. Pharmaceutical preparation according to one of claims 1 to 15, characterized in that it vzw. is in the form of a liquid, tablets, granules, capsules, powder, lyophilisates.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10154464 | 2001-11-08 | ||
DE10154464A DE10154464B4 (en) | 2001-11-08 | 2001-11-08 | Orally administrable pharmaceutical preparation comprising liposomally encapsulated taxol |
PCT/DE2002/004120 WO2003039437A2 (en) | 2001-11-08 | 2002-11-06 | Orally administered pharmaceutical preparation comprising liposomically encapsulated paclitaxel |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1443904A2 true EP1443904A2 (en) | 2004-08-11 |
Family
ID=7704785
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02785050A Withdrawn EP1443904A2 (en) | 2001-11-08 | 2002-11-06 | Orally administered pharmaceutical preparation comprising liposomically encapsulated paclitaxel |
Country Status (6)
Country | Link |
---|---|
US (1) | US20050019386A1 (en) |
EP (1) | EP1443904A2 (en) |
JP (1) | JP2005511578A (en) |
AU (1) | AU2002350386A1 (en) |
DE (1) | DE10154464B4 (en) |
WO (1) | WO2003039437A2 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6750246B1 (en) | 2000-02-03 | 2004-06-15 | Bristol-Myers Squibb Company | C-4 carbonate taxanes |
EP1643972A4 (en) * | 2003-06-27 | 2010-01-20 | Smithkline Beecham Corp | Stabilized topotecan liposomal composition and methods |
US20080102111A1 (en) * | 2005-03-09 | 2008-05-01 | Hiromichi Imanaka | Anticancer Composition for Oral Use Comprising Liposome Containing Phytosterols and Prevention or Treatment for Cancer Using the Liposome |
JP2009538317A (en) * | 2006-05-26 | 2009-11-05 | バイエル ヘルスケア リミティド ライアビリティ カンパニー | Drug combinations using substituted diarylureas for cancer treatment |
KR20080101056A (en) * | 2007-05-15 | 2008-11-21 | 한국화학연구원 | Phospholipid nanospheres for solubilization of diterpenoid alkaloid and preparation |
US20090088393A1 (en) * | 2007-09-28 | 2009-04-02 | Zomanex, Llc | Methods and formulations for converting intravenous and injectable drugs into oral dosage forms |
EA022182B1 (en) * | 2012-12-24 | 2015-11-30 | Общество С Ограниченной Ответственностью "Технология Лекарств" | Method of producing docetaxel liposome form |
EP3358156A4 (en) * | 2015-10-02 | 2019-07-31 | Kabushiki Kaisha Riken | Sintered valve seat |
CN113384705A (en) * | 2021-06-28 | 2021-09-14 | 西南大学 | Preparation of poloxamer modified liposome and application of poloxamer modified liposome in oral drug delivery |
KR20240047637A (en) * | 2022-10-05 | 2024-04-12 | 한국과학기술연구원 | Pharmaceutical composition for oral administration comprising taxane and preparing method thereof |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5616688A (en) * | 1981-09-08 | 1997-04-01 | The Rockefeller University | Macrophage-derived inflammatory mediator (MIP-1α and MIP-1β) |
US5411947A (en) * | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
CA2132711C (en) * | 1992-03-23 | 2005-02-08 | Aquilar Rahman | Liposome encapsulated paclitaxel and a method of using the same |
AU6832794A (en) * | 1993-05-19 | 1994-12-12 | Liposome Company, Inc., The | Liposome having a multicomponent bilayer which contains a bioactive agent as an integral component of the bilayer |
US5415869A (en) * | 1993-11-12 | 1995-05-16 | The Research Foundation Of State University Of New York | Taxol formulation |
DE4447770C2 (en) * | 1994-08-20 | 2002-12-19 | Max Delbrueck Centrum | Process for the production of liposomally encapsulated taxol |
US5580899A (en) * | 1995-01-09 | 1996-12-03 | The Liposome Company, Inc. | Hydrophobic taxane derivatives |
GB9514878D0 (en) * | 1995-07-20 | 1995-09-20 | Danbiosyst Uk | Vitamin E as a solubilizer for drugs contained in lipid vehicles |
US6106858A (en) * | 1997-09-08 | 2000-08-22 | Skyepharma, Inc. | Modulation of drug loading in multivescular liposomes |
US6090407A (en) * | 1997-09-23 | 2000-07-18 | Research Development Foundation | Small particle liposome aerosols for delivery of anti-cancer drugs |
US6146659A (en) * | 1998-07-01 | 2000-11-14 | Neopharm, Inc. | Method of administering liposomal encapsulated taxane |
US6153217A (en) * | 1999-01-22 | 2000-11-28 | Biodelivery Sciences, Inc. | Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents |
US7217735B1 (en) * | 1999-04-09 | 2007-05-15 | Au Jessie L-S | Methods and compositions for enhancing delivery of therapeutic agents to tissues |
GB2355656B (en) * | 1999-08-17 | 2004-04-07 | Galena As | Pharmaceutical compositions for oral and topical administration |
US6656504B1 (en) * | 1999-09-09 | 2003-12-02 | Elan Pharma International Ltd. | Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions |
EP1317270A1 (en) * | 2000-09-08 | 2003-06-11 | Pharmacia Italia S.p.A. | Exemestane for the treatment of oestrogen-dependent cancers |
US20040092583A1 (en) * | 2001-01-02 | 2004-05-13 | Elizabeth Shanahan-Prendergast | Treatment for inhibiting neoplastic lesions |
-
2001
- 2001-11-08 DE DE10154464A patent/DE10154464B4/en not_active Expired - Fee Related
-
2002
- 2002-11-06 US US10/495,039 patent/US20050019386A1/en not_active Abandoned
- 2002-11-06 AU AU2002350386A patent/AU2002350386A1/en not_active Abandoned
- 2002-11-06 EP EP02785050A patent/EP1443904A2/en not_active Withdrawn
- 2002-11-06 WO PCT/DE2002/004120 patent/WO2003039437A2/en active Application Filing
- 2002-11-06 JP JP2003541531A patent/JP2005511578A/en active Pending
Non-Patent Citations (1)
Title |
---|
See references of WO03039437A2 * |
Also Published As
Publication number | Publication date |
---|---|
DE10154464A1 (en) | 2003-05-22 |
AU2002350386A1 (en) | 2003-05-19 |
DE10154464B4 (en) | 2005-10-20 |
US20050019386A1 (en) | 2005-01-27 |
WO2003039437A3 (en) | 2003-07-10 |
WO2003039437A2 (en) | 2003-05-15 |
JP2005511578A (en) | 2005-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE4447770C2 (en) | Process for the production of liposomally encapsulated taxol | |
DE60115045T2 (en) | IMPROVED LIPOSOMAL CAMPTOTHECINE AND ITS USES | |
US5147859A (en) | Complexes of glycerrhetinic acid with phospholipids and pharmaceutical and cosmetic compositions containing them | |
DE69531701T2 (en) | SPHINGOSOME WITH IMPROVED DRUG RELEASE | |
DE69735949T2 (en) | COMPOSITION SUITABLE FOR THE TREATMENT OF HORSE MILF | |
US7122553B2 (en) | Liposomal formulation of irinotecan | |
US20030219476A1 (en) | Liposomal formulation of mitoxantrone | |
DE1792410A1 (en) | Pharmacological composition and process for its preparation | |
WO2003039437A2 (en) | Orally administered pharmaceutical preparation comprising liposomically encapsulated paclitaxel | |
DE60025494T2 (en) | EPOTHILONE COMPOSITIONS | |
EP1135193A1 (en) | Agents provided for treating tumors, based on liposomes, and containing tamoxifen | |
DE4408011C1 (en) | Liposomes for tumour therapy | |
JP2003516348A (en) | Pharmaceutical preparation containing cytostatic and electron acceptor for cancer treatment | |
KR102068265B1 (en) | Composition comprising an onion extract and liposomes | |
EP2301551A1 (en) | Use of alkyl phosphocholines in combination with antitumor medicaments | |
EP0858807B1 (en) | Use of dopamine receptor antagonists in palliative tumor therapy | |
EP0470437A1 (en) | Aqueous liposome system | |
JP6322575B2 (en) | Topical formulation containing lipid microcapsule delivery vehicle and use thereof | |
DE4134158C2 (en) | Use of carboplatin in lyotrophic mesophases to overcome leukopenia caused by cytostatics | |
JP2003512313A (en) | Liposomal preparation of 6,9-bis-[(2-aminoethyl) -amino] benzo [g] isoquinoline-5,10-dionedimaleate | |
DE60115429T2 (en) | Anticancer combinations of DMXAA and paclitaxel or docetaxel | |
WO2001070220A1 (en) | A method of administering liposomal encapsulated taxane | |
JPH04169531A (en) | Liposome preparation containing lipo-soluble platinum complex | |
DE69928805T2 (en) | Liposomal formulations of busulfan | |
WO2009089845A1 (en) | Agent for intra-articular injection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20040607 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
17Q | First examination report despatched |
Effective date: 20080714 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20110618 |